#153241

Mouse fibrosarcoma VEGF188 Cell Line

Please Enter Your Email ID
Email ID

Cat. #153241

Mouse fibrosarcoma VEGF188 Cell Line

Cat. #: 153241

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Organism: Mouse

Tissue: Embryo

Disease: Cancer

Model: Immortalised Line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Gillian Tozer

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Mouse fibrosarcoma VEGF188 Cell Line
  • Alternate name: VEGF-A, VEGF12, VEGF164, VEGF188
  • Research fields: Cancer;Cell signaling and signal transduction;Developmental biology;Drug development;Metabolism
  • Tool sub type: Continuous
  • Parental cell: MEF
  • Organism: Mouse
  • Tissue: Embryo
  • Disease: Cancer
  • Growth properties: Adherent
  • Model: Immortalised Line
  • Conditional: No
  • Description: Mouse fibrosarcoma cell lines that are capable of expressing all vascular endothelial growth factor (VEGF) isoforms (control) or only single isoforms of VEGF (VEGF120, VEGF164, or VEGF188) were developed under endogenous VEGF promoter control. Using Cre/Lox technology, mice expressing all or only single isoforms of VEGF, known as Vegfa120/120, Vegfa164/164, and Vegfa188/188 mice were developed. Primary fibroblasts were isolated from mouse embryos that were produced by heterozygous breeding pairs of mice expressing single or all isoforms of vascular endothelial growth factor-A (VEGF-A) on Swiss background. Fibroblasts were immortalized and oncogenically transformed by retroviral transduction with SV40 and HRAS (characterised in Tozer et al., 2008. Cancer Res; 68: (7)). The original rationale for the development of these cell lines relates to the fact that tubulin-binding vascular-disrupting agents (VDA) are currently in clinical trials for cancer therapy but the factors that influence tumour susceptibility to these agents are poorly understood. Researchers evaluated the consequences of modifying tumour vascular morphology and function on vascular and therapeutic response to combretastatin-A4 3-O-phosphate (CA-4-P), which was chosen as a model VDA. The cell lines themselves could be potentially valuable for the commercial/pharmaceutical industry.
  • Production details: Using Cre/Lox technology, mice expressing all or only single isoforms of VEGF, known as Vegfa120/120, Vegfa164/164, and Vegfa188/188 mice were developed. Primary fibroblasts were isolated from mouse embryos that were produced by heterozygous breeding pairs of mice expressing single or all isoforms of vascular endothelial growth factor-A (VEGF-A) on Swiss background. Fibroblasts were immortalized and oncogenically transformed by retroviral transduction with SV4...
  • Cellosaurus id: CVCL_HG22

Target Details

  • Target: VEGF120

Handling

  • Format: Frozen
  • Growth medium: High glucose DMEM (Invitrogen) medium, L-glutamine, FCS, G-418 and puromycin. antibiotics G-418 and puromycin
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

Related Tools

  • Related tools: Mouse fibrosarcoma Luciferase2 mStrawberry VEGF188 Cell Line

References

  • Tozer et al. 2008. Cancer Res. 68(7):2301-11. PMID: 18381437.
  • Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.